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Steady and presteady kineticsHuman immunodeﬁciency virus type-1 (HIV-1) reverse transcriptase (RT) has a unique tight binding to dNTP
substrates. Structural modeling of Ala-114 of HIV-1 RT suggests that longer side chains at this residue can re-
duce the space normally occupied by the sugar moiety of an incoming dNTP. Indeed, mutations at Ala-114
decrease the ability of RT to synthesize DNA at low dNTP concentrations and reduce the dNTP-binding afﬁnity
(Kd) of RT. However, the Kd values of WT and A114C RT remained equivalent with an acyclic dNTP substrate.
Finally, mutant A114 RT HIV-1 vectors displayed a greatly reduced transduction in nondividing human lung
ﬁbroblasts (HLFs), while WT HIV-1 vector efﬁciently transduced both dividing and nondividing HLFs. Togeth-
er these data support that the A114 residue of HIV-1 RT plays a key mechanistic role in the dNTP binding of
HIV-1 RT and the unique viral infectivity of target cell types with low dNTP pools.
© 2011 Elsevier Inc. All rights reserved.Introduction
Human immunodeﬁciency virus type-1 (HIV-1) belongs to the
genus lentivirus in the family Retroviridae. Most retroviruses in this
family, such as alpha, beta, gamma and deltaretroviruses are oncore-
troviruses, which exclusively infect dividing cells. Lentiviruses howev-
er, productively infect both dividing CD4+ T cells and nondividing
cells such as macrophages, which have been shown to act as long-
term HIV-1 viral reservoirs (Igarashi et al., 2001; Lewis and
Emerman, 1994; Lewis et al., 1992; Weinberg et al., 1991). Due to
this dual cellular tropism, the HIV-1 encoded DNA polymerase, re-
verse transcriptase (RT), must function in two distinct dNTP substrate
environments. The ﬁrst, activated CD4+ T cells, have a cellular dNTP
concentration around 1.4–2.5 μM; the second, macrophages, have a
much lower concentration of about ~40 nM (Diamond et al., 2004;
Kennedy et al., 2010). Our earlier pre-steady-state kinetic analysis
reported that HIV-1 RT has a high binding afﬁnity to dNTPs with a Kd
near 1 μM, while the Kd value of murine leukemia virus (MuLV) RT
was found to be approximately 40 μM (Skasko et al., 2005; Weiss et
al., 2004). We also observed that HIV-1 variants harboring RTmutants
with a decreased dNTP binding afﬁnity, failed to replicate in macro-
phages and cell types harboring low dNTP concentrations. However,x 672, Department of Microbi-
l Center, Rochester, New York
im).
t.
rights reserved.these mutant RTs do not signiﬁcantly alter the viral replication in
cells containing high dNTP concentrations (Jamburuthugoda et al.,
2008; Weiss et al., 2002). Therefore, these studies suggested that the
tighter dNTP binding afﬁnity of RT contributes to the unique replication
capability of HIV-1 in nondividing cells containing limited dNTP pools.
The DNA polymerase active site of HIV-1 RT contains a series of
residues that are responsible for the binding and/or incorporation of
dNTPs onto the 3′ end of a primer (Harris et al., 1998). The residues
A113, A114, Y115, Q151, and M184 are found near the 3′ OH of an in-
coming dNTP (Fig. 1) and are all highly conserved in HIV-1 RT as well
as other lentiviral RTs (Cases-González and Menéndez-Arias, 2005;
Huang et al., 1998; Lowe et al., 1991; Pandey et al., 1996). Y115
(green) appears to play a key role as a gate, discriminating dNTPs
from rNTPs (Boyer et al., 2000; Gao et al., 1997; Joyce, 1997;
Martín-Hernández et al., 1996). Mutations at residue M184 (purple),
which naturally contribute to mismatch selectivity, are frequently
found in HIV-1 drug resistant patients (Menéndez-Arias, 2008;
Pandey et al., 1996; Ray et al., 2002; Svedhem et al., 2007; Yang et
al., 2008; Yoshimura et al., 1999). M184I, for example, is a transient
3TC resistant mutation, ultimately resulting in M184V (Frost et al.,
2000; Mulder et al., 2008; Svedhem et al., 2007). It was found that
the beta branched side chain of isoleucine sterically blocks the entry
of 3TC into the active site of RT (Saraﬁanos et al., 1999). We have
shown that the M184I mutation also alters the binding of RT to
dNTPs, raising the Kd to 56 μM, which is similar to the Kd value of
MuLV RT (Skasko et al., 2005). The M184I mutation was also found
to change the tropism of an HIV-1 vector, preventing it from trans-
ducing human macrophages (Jamburuthugoda et al., 2008; Skasko
et al., 2005). We observed a similar outcome with Q151N, a non-
(A) A114 WT (B) A114S  
dTTP dTTP
Ser114Ala114
Q151
Y115
A113
(C) A114C  
M184
dTTP
Cys114
Fig. 1. Structural modeling of the HIV-1 RT residue 114 mutants at the dNTP-binding pocket. (A) The position of the HIV-1 RT A114 residue (teal) in relation to an incoming dTTP
substrate (blue/red), and Y115 (green), A113 (yellow), M184 (purple) and Q151 (light blue), is shown using coordinate set 1rtd.pdb from the Protein Data Bank (Huang et al.,
1998). (B) and (C) The positions of the S114 and C114 mutant residues were constructed by the program PyMOL (Schrodinger, 2010) that manually selected the optimal rotamer
for serine or cysteine at residue 114 of HIV-1 reverse transcriptase from Huang et al. (1998). These were then minimized with AMBER 9.0 with 500 cycles (250 steepest descent)
with implicit solvent. Arrows indicate the 3′ OH of the incoming dTTP. Volume of amino acids was calculated as described previously (Zamyatnin, 1984).
394 S.K. Van Cor-Hosmer et al. / Virology 422 (2012) 393–401clinical RT mutation (light blue) (Diamond et al., 2004). The gluta-
mine at 151 interacts with the 3′ OH of an incoming dNTP through
a hydrogen bond; however, when mutated to asparagine, the Kd of
RT for substrate is raised to 257 μM (Weiss et al., 2002). HIV-1 vectors
carrying this mutation also fail to transduce primary human macro-
phages but maintain a signiﬁcant level of transduction in cells with
high dNTP pools. Principally, this work suggests that the manipula-
tion of certain residues within the active site of RT can impact the
dNTP binding afﬁnity through different mechanisms, which result in
altered HIV-1 cellular tropism (Diamond et al., 2004).
The A114 residue contributes a nonspeciﬁc Van der Waals interac-
tion with the incoming dNTP, unlike Q151, which interacts speciﬁcal-
ly with the sugar moiety of the dNTP (3′ OH) (Huang et al., 1998;
Menéndez-Arias, 2008). The Stanford HIV Database, includes 19 iso-
lates carrying mutations at A114 however, most isolates have been
previously shown to be detrimental to RT activity (Halvas et al.,
2000; Rhee et al., 2003). A steady-state study demonstrated that a de-
crease in the Km values of RT could be correlated with the size of the
mutated side chain present at this residue (Cases-González and
Menéndez-Arias, 2005). However, the effect of mutations at A114
on the dNTP binding of HIV-1 RT has not been characterized. Structur-
ally, A114 is located in a pocket that binds the 3′ OH of an incoming
dNTP, which is in close proximity to the dNTPs sugar moiety
(Huang et al., 1998). In this study we hypothesize that mutations at
residue 114 of RT to amino acids with larger side chains may reduce
the volume of the HIV-1 dNTP-binding pocket, resulting in a de-
creased space for the sugar moiety of normal dNTPs to reside, but
conceivably not dNTP analogs lacking the intact sugar moiety. The re-
quirement of a certain volume in the active site of RT for an incomingdNTP would represent a unique mechanism of substrate binding; un-
like the mutation Q151N, that decreases the dNTP binding through a
loss of interaction or M184I, which results in a steric clash with the
incoming dNTP. We tested this hypothesis to understand the molecu-
lar interaction of HIV-1 RT with its dNTP substrate, which plays a key
role in HIV-1 proviral DNA synthesis and viral cellular tropism.
Results
Structural view of the wild type and mutant residues at HIV-1 RT position
114
First, in order to deﬁne the position of the methyl side chain of the
HIV-1 RT A114 residue with respect to the incoming dNTP, we con-
structed a model of the dNTP-binding pocket of RT in a ternary com-
plex bound to template/primer and dNTP substrate using a previously
determined crystal structure (Huang et al., 1998). As illustrated in
Fig. 1A, the methyl side chain of A114 (teal blue) lies near the sugar
moiety of the incoming dTTP (light blue/red). More speciﬁcally, the
methyl side chain of A114 protrudes from the surface of the dNTP-
binding pocket toward the sugar moiety of the incoming dNTP, form-
ing a distance of 3.37 Å between the Cβ of A114 and the 3′ OH (pink
arrows) of the incoming dNTP (Cases-González and Menéndez-
Arias, 2005). This unique geometric position of A114 led us to hy-
pothesize that an increased side chain volume at this residue would
conﬂict with the sugar moiety of an incoming dNTP. Indeed, the re-
duced space for the sugar moiety of a dNTP appears to be inevitable
after calculating the distance of A114S to the 3′ OH, 1.96 Å. However,
the distance between the mutated residue and the 3′ OH does not
395S.K. Van Cor-Hosmer et al. / Virology 422 (2012) 393–401account for alterations in volume of the binding pocket. After model-
ing the positions of A114S (Fig. 1B), A114C (Fig. 1C), and volume
(Table S1) of other additional amino acids, it is apparent that by in-
crementally extending the side chain of residue 114, the volume of
the 3′ OH binding pocket decreases. Therefore, we hypothesized
that mutations at residue 114 with longer side chains may decrease
the high dNTP-binding afﬁnity of HIV-1 RT, ultimately leading to a re-
duction in the capability of HIV-1 to replicate in cells harboring low
dNTP concentrations.
dNTP concentration dependent DNA polymerization by WT and A114
mutant HIV-1 RT proteins
To test our hypothesis, we constructed and puriﬁed a series of
HIV-1 NL4-3 RT A114 mutant proteins with increasingly longer side
chains: A114S, A114C, A114V and A114I. First, we investigated the
dNTP concentration dependent DNA polymerase activity of wild
type (WT) and the A114 HIV-1 RT mutants using a primer extension
assay for steady-state multiple dNTP incorporations. We expected
that mutations at this residue may restrict the entry of a dNTP and
thus would display reduced polymerase activities at lower dNTPPrimer:
Template:
F
[dNTP]*
lanes
RTs:
1 2 3 4 5 6 7 8 1 2 3 4
A B
**
P
RTs:
1 2 3 4 5 6 7 8 1 2 3
[dNTP]
lanes
F ED
*
P
*dNTP concentrations (lanes 1-8) 250, 100, 25, 5, 1, 0.
Fig. 2. dNTP concentration dependent reverse transcription activity of HIV-1 RT variants. St
using a 5′ end 32P-labeled 23-mer A primer (P) annealed to a 38-mer RNA template was
(E) A114I showing ~50% of primer extension with 250 μM dNTPs (lane 1) at 37 °C for 5 mi
25, 5, 1, 0.5, 0.25, and 0.1 μM). F: 38 nt fully extended products. “*”: Lane 4 with 5 μM dNTPconcentrations, when compared to WT HIV-1 RT. This assay uses a
5′ end 32P-labeled DNA 23-mer primer (P) annealed to a 38-mer
RNA template (T) and varying concentrations of dNTPs. These reac-
tions were repeated in triplicate (data not shown) with representa-
tive gels shown in Fig. 2. The RT protein concentrations for this
assay were normalized by an activity that gave ~50% extension of
the primer at a saturating dNTP concentration (250 μM), under stan-
dard reaction conditions (5 min and 37 °C). This reaction was then re-
peated with gradually decreasing dNTP concentrations. As shown in
Fig. 2A, WT A114 HIV-1 RT generated substantial amounts of the
fully extended products (F) even at 5 μM (lane 4), and continued
showing detectable dNTP incorporation as low as 0.1 μM. However,
the A114S (Fig. 2B) and A114C (Fig. 2C) RT mutants, with slightly lon-
ger side chains, demonstrated reduced activity compared to WT RT at
0.25 μM (see lane 4 and “*”). The activity of A114V was greatly re-
duced even at a 2.5 μM dNTP concentration (Fig. 2D). These results
were expected due to the large addition at 114 of the beta branched
side chain of valine, compared to the relatively minimal alterations
of an OH or SH group addition with the mutations A114S or A114C.
Lastly, when the residue 114 was mutated to an even larger side
chain, A114I, RT failed to display any detectable primer extension}dNTP incorporation
5 6 7 8 1 2 3 4 5 6 7 8
C
*
4 5 6 7 8
5, 0.25, 0.1µM 
eady-state incorporation rates of dNTPs by WT RT or A114 mutants were measured by
extended by HIV-1 RT proteins, (A) WT A114, (B) A114S, (C) A114C, (D) A114V, and
n. The reactions were repeated with decreasing dNTP concentrations (lanes 1–8: 100,
.
Table 1
Steady-state kinetics of WT and residue 114 mutant HIV-1 RT proteins with dTTP and
acyTTP.
Enzyme dNTPs akcat (min−1) Km (μM) (fold change
compared to WT)
akcat/Km
(μM−1·min−1)
WT dTTP 1.91±0.09 0.29±0.07
(1×)
6.61
acyTTP 1.91±0.05 0.97±0.28
(1×)
1.97
A114S dTTP 7.92±0.26 5.36±1.94
(18×)
1.48
acyTTP 7.74±0.93 9.6±2.73
(10×)
0.81
A114C dTTP 12.95±1.19 7.14±2.73
(25×)
1.81
acyTTP 11.95±0.56 2.54±0.76
(3×)
4.70
A114V dTTP 1.38±0.02 80.60±44.97
(278×)
0.02
acyTTP 1.13±0.15 9.37±3.05
(10×)
0.12
a kcat=(Vmax/enzyme concentration)×10−3.
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exhibited a detectable activity at high dNTP concentrations. This ex-
periment demonstrates that WT RT is efﬁcient at reverse transcrip-
tion in both high and low dNTP concentrations; however, mutations
at the residue 114 of HIV-1 RT with increasing side chain sizes grad-
ually decrease the capability of RT to polymerize DNA, speciﬁcally at
low dNTP concentrations. This supports the prediction made in the
structural model in Fig. 1 and is consistent with a previously pub-
lished steady-state analysis of A114 RT mutants (Cases-González
and Menéndez-Arias, 2005).Steady-state activity of HIV-1 RT and A114 mutants with dTTP and
acyTTP
The model in Fig. 1 predicts that bulky mutant side chains at the
residue 114 could reduce the volume of the dNTP substrate-binding
pocket, speciﬁcally the space where the sugar moiety resides. This re-
duction of available volume maybe responsible for the decreased rateFig. 3. Incorporation comparison of WT and A114C HIV-1 RT with dNTP and acyTTP analog co
or WT RT was measured. (A) Chemical structure of dTTP and acyTTP. (B) Incorporation com
annealed to the 38-mer RNA template was extended by WT and A114C RTs. Concentrations
strate control, P: primer, E: extended product.of dNTP incorporation observed at low dNTP concentrations (Fig. 2)
and the increased Km values (Cases-González and Menéndez-Arias,
2005; Huang et al., 1998). Next, we tested our hypothesis by decreas-
ing the sugar moiety size of the incoming nucleotide substrate. We
predicted that the HIV-1 RT mutants with bulkier side chains might
have an enhanced capability to incorporate a dNTP analog with a
much smaller sugar moiety lacking the 2′ and 3′ carbons of the
sugar ring, acyTTP (Fig. 3A), which would require less space
(Jamburuthugoda et al., 2005), compared to normal dNTPs. We
found that both WT and A114C RT have equal primer template exten-
sion at low concentrations of acyTTP; however, A114C RT displayed
reduced extension at low dTTP concentrations when compared to
WT (Fig. 3B). This further suggests that an increased side chain vol-
ume at residue 114 will conﬂict directly with the 3′ OH of an incom-
ing dNTP.
We next determined steady-state Km and Kcat values for WT and
residue 114 mutants, for quantitative comparison of single nucleotide
incorporation kinetics for dTTP and acyTTP with a 5′ end 32P labeled
23-mer T primer annealed to the 38-mer RNA template. First, as
shown in Table 1, the Km values of A114S, A114C and A114V RTs
with normal dTTP incorporation continue to incrementally increase
by 18, 25 and 278-folds, compared to the Km value of wild type RT,
which is consistent with the previous observation (Menéndez-Arias,
2008). However, when the same analysis was conducted with acyTTP
incorporation, A114S, A114C and A114V RT displayed only 10, 3 and
10-fold increase in Km, when compared to wild type. This lower in-
crease of the A114 mutant RT Km values with acyTTP compared to
dTTP is consistent with our hypothesis; it further demonstrates that
the entry of acyTTP into the dNTP binding pocket is less affected by
the larger side chain volumes at residue 114, compared to the entry
of dTTP. This is most likely due to the large sugar moiety volume of
the natural dTTP compared to the acyTTP, which requires a much
smaller space in the dNTP-binding pocket than the normal dTTP. In
addition, this further suggests that the absence of the 2′ and 3′ car-
bons space in acyTTP, complements the large side chain volumes of
the A114C and A114V mutant RTs, supporting the idea that the side
chain of HIV-1 RT residue 114 lies proximal to the 2′ and 3′ carbons
of the incoming dNTP substrate. However, A114I was unable to incor-
porate acyTTP even at a 200 μM dNTP concentration (data not
shown), suggesting that the volume of this side chain may conﬂict
with more than just the ribose ring of an incoming dNTP.ntaining a modiﬁed sugar moiety. The incorporation of either acyTTP or dTTP by A114C
parison of WT and A114C with dTTP and acyTTP. A 5′ end 32P labeled 23-mer T primer
of the nucleotides were 250,100, 25, 5, 1, 0.5, 0.25, and 0.1 μM (lanes 1–8). C: No sub-
397S.K. Van Cor-Hosmer et al. / Virology 422 (2012) 393–401Pre-steady-state kinetic analysis for the dNTP binding afﬁnity of WT and
A114C mutant HIV-1 RT proteins
Next, we tested if mutations at the A114 residue affected the
dNTP-binding step of DNA polymerization. To test this we performed
a pre-steady-state kinetic analysis and measured the dNTP binding
afﬁnity (Kd) and conformational change/catalysis (kpol) of WT RT
and the mutant A114C that displayed a milder defect in steady-state
kinetics. First, the active site concentrations of WT and A114C RT pro-
teins were determined with an excess of T/P using a rapid quench
technology. This experiment is done to ascertain the concentration
of active protein present in the WT and A114C RT preparations
(Fig. 4A). The dNTP concentration dependent pre-steady state ratesA
B WT
C WT
15
5
10
0
0 14 28 42 56 70
acylTTP (uM)
WT
Fig. 4. Active site determination and dNTP titration curves of WT and A114C HIV-1 RT prote
TTP. Reactions were carried out at the indicated times by mixing together pre-bound RT (100
methods). The data was ﬁt into the burst equation (Eq. (1) in Materials and methods) as ind
and (C) dNTP and acyTTP (respectively) titration curves of WT and A114C RTs under the p
ferent primers for each of the four nucleotides and acyTTP. Results were ﬁt into Eq. (2) (i
are summarized in Table 2 for all ﬁve substrates.(kobs) were then determined with excess of RT protein for all four
dNTPs and acyTTP. The experimentally determined kobs values were
plotted to calculate the Kd and kpol values of WT and A114C proteins
with all four dNTPs, as described in the Materials and methods sec-
tion. As shown in Table 2, the A114C mutant demonstrated a
2.5–4.8 fold higher Kd than WT RT, with little difference in the kpol
values. This further supports the idea that mutations at A114 reduce
the dNTP binding afﬁnity of HIV-1 RT. Moreover, as shown in
Table 2 and Fig. 4C, both the kpol and Kd of A114C compared to WT
were not affected when acyTTP, a dNTP analog that lacks 2′ and 3′
carbons of sugar ring, was used as a substrate. This indicates that un-
like dTTP, bulky side chains at position 114 do not affect the entrance
of acyTTP. Taken together, observations from the pre-steady-stateA114C
20
5
10
15
0
0 20 40 60 80
acylTTP (uM)
A114C
A114C
ins. (A) Pre-steady and steady-state kinetics of WT and A114C HIV-1 RT incorporating
nM)·T/P (100 nM) with 800 μM TTP under rapid quench conditions (see Materials and
icated by the solid line, which provides a measure of the active concentration of RT. (B)
re-steady-state conditions. kobs was measured at varying concentrations with four dif-
ndicated by the solid line) to calculate the corresponding values of kpol and Kd, which
Table 2
Pre-steady-state kinetic values of WT and A114C RT proteins with four dNTPs.
Enzyme dNTPs kpol (s−1) Kd (μM) (fold
difference)
kpol/Kd
(μM−1·s−1)
WT dTTP 85.7±7.3 3.4±0.6 25.2
dGTP 39.8±1.4 1.7±0.3 23.4.8
dCTP 138.8±12.3 0.6±0.3 231.3
dATP 69.6±5.4 1.2±0.4 58.0
acyTTP 14.12±1.2 6.9±2.7 2.1
dTTP 242.3±41.1 8.4±4.0 (2.5×) 28.8
A114C dGTP 33.3±2.9 8.1±2.1 (4.8×) 4.1
dCTP 261.2±18.9 2.1±0.6 (3.5×) 124.3
dATP 50.5±8.5 4.3±2.1 (3.6×) 11.7
acyTTP 18.2±1.6 (1.3×) 5.7±1.4 (1.2×) 3.2
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114 reduce the dNTP binding afﬁnity of HIV-1 RT, due to a volume re-
quirement of the incoming dNTP sugar moiety.
HIV-1 transduction in human lung ﬁbroblasts with different dNTP
concentrations
Both pre-steady-state and steady-state kinetic analysis conﬁrmed
that mutations at 114 reduce the efﬁciency of RTs DNA synthesis at
low dNTP concentrations when compared to WT (Fig. 2), which is aA A
Serum SerumStarved
B
A114S  WT  
*
0
25
50
75
100
%
 Tr
an
sd
uc
tio
n
Fig. 5. Transduction of human lung ﬁbroblasts with HIV-1 vectors containing WT and A114
expression. (A) HLFs were grown in media supplemented with 10% serum, serum starved
(5.5×105 pg/mL) of WT, A114S, A114C or A114V D3HIV-GFP vectors. The transduction of
dark/GFP ﬁelds. (B) The cells were harvested for FACS analyzed for the GFP positive cells. T
a t test with a P value of b0.0001, between the conditions serum and serum starved.result of RTs reduced dNTP binding when a mutant side chain with
a larger volume exists at residue114 (Table 2). Thus, these biochemi-
cal observations further predict a dNTP concentration dependence of
RT during proviral DNA synthesis that would impact vector transduc-
tion in cells containing low dNTP concentrations, but not in cells con-
taining high dNTP concentrations.
To test this prediction, we carried out an HIV-1 transduction study
using human lung ﬁbroblasts (HLFs). HLFs have been used as a
model system for both dividing and nondividing cells as their dNTP
concentrations can be controlled through cell cycle manipulation
(Jamburuthugoda et al., 2008; Skasko and Kim, 2008) or deoxynu-
cleoside (dN) treatment (Jamburuthugoda et al., 2006). Dividing
HLFs cultured in 10% serum have an intracellular dNTP concentration
of approximately 150–300 nM (Jamburuthugoda et al., 2006) which
is higher than the dNTP concentration found in human macrophages
(~50 nM), but much lower than activated CD4+ T cells (1.4–2.5 μM)
(Diamond et al., 2004). Treating dividing and nondividing HLFs with
deoxynucleosides (dNs) elevates their cellular dNTP concentrations
to 50 μM and ~1 μM, respectively. By altering the dNTP concentra-
tions in HLFs, we were able to control the conditions for viral DNA
synthesis of HIV-1 transduction (Jamburuthugoda et al., 2008). We
introduced the A114S, A114C or A114V mutation into the pol gene
of an HIV-1 vector. Equal p24 amounts of all vectors were used to
transduce to HLFs grown under three culture conditions: 1) 10%
serum, 2) serum starved, or 3) serum starved with 1 mM dN114C  
Serum Starved
1mM dN
WT
A114S
A114C
A114V
Serum
Serum
Starved
Serum
Starved
1mM dNs
A114V  
S RTs. HLFs were transduced with WT or A114 mutant vectors and monitored for GFP
, or serum starved with 1 mM dNs. Cells were transduced using an equal p24 amount
the vectors was monitored after 48 for GFP expression by microscope in bright and
he experiment was conducted in triplicate. “*” Indicates signiﬁcance as preformed by
399S.K. Van Cor-Hosmer et al. / Virology 422 (2012) 393–401treatment. The cells were visualized in both bright and dark ﬁelds
(Fig. 5A), and the transduction efﬁciency was determined by FACS
analysis for GFP expression (Fig. 5B). As shown in Fig. 5A, WT RT vec-
tor was able to efﬁciently transduce HLFs under all three conditions,
indicating that WT HIV-1 RT can efﬁciently synthesize DNA even at
low dNTP concentrations found in the nondividing HLFs. The A114S
vector displayed WT levels of transduction in dividing HLFs (grown
in 10% serum: Figs. 5A and B). However, the A114S vector showed
signiﬁcantly reduced transduction in serum starved HLFs (Figs. 5A
and B “*”). This suggests that the transduction of an HIV-1 vector car-
rying the A114S mutation is speciﬁcally affected in cells containing
low dNTP concentration, but not in dividing HLFs with high cellular
dNTP concentrations. Indeed, the reduced transduction of the A114S
vector could be rescued by 1 mM dN treatment in serum starved
HLFs (Figs. 5A and B). Further indicating the impaired transduction
capability of the A114S vector was due to the limited cellular dNTP
pools in serum starved cells (Aquaro et al., 2005). Unlike A114S and
WT, the A114C vector displayed reduced transduction in HLFs
grown in serum. This transduction decreased further in serum-
starved cells and was unable to be rescued by dN treatment. This
again indicates a larger dNTP-binding defect generated with this mu-
tation when compared toWT or A114S. The A114V failed to transduce
HFLs grown in serum-starved media and demonstrated almost unde-
tectable transduction levels in HLFs grown in serum or serum-starved
media supplemented with dNs. Taken all together, this indicates that
the transduction of an HIV-1 vector can be reduced by increasing the
side chain volume present at A114 and that this transduction can be
further decreased by limiting the cellular dNTP concentration.
Discussion
Nucleoside RT inhibitors (NRTIs) are one of the key anti-retroviral
agents for the treatment of HIV-1 infected patients. NRTIs enter the
dNTP-binding pocket of HIV-1 RT during reverse transcription
through competition with cellular dNTP substrates. Thus, it is impor-
tant to understand the molecular basis of HIV-1 RT natural substrate
selection during viral replication. Importantly, HIV-1 uniquely repli-
cates both in activated dividing CD4+ T cells and terminally dif-
ferentiated nondividing macrophages, which contributes to its
pathogenesis. It has been shown that these two natural target cell
types harbor vastly different cellular dNTP pools; macrophages have
20–50 nM dNTPs, which is a much lower concentration than the Kd
of most known cellular DNA polymerases, whereas T cells contain
around 1.4–2.5 μM dNTPs (Diamond et al., 2004). It has also been
shown that other DNA viruses replicating in macrophages (i.e. herpes
simplex virus) (Ho et al., 2004; Kaplitt and Pfaff, 1996; Okada et al.,
2002; Sulpizi et al., 2001) require their own dNTP synthesis machin-
ery (i.e. thymidine kinase) to provide the virus with an adequate sup-
ply of dNTP substrates for DNA replication. HIV-1 and other
lentiviruses lack this viral dNTP biosynthesis machinery. This raises
the question of how lentiviruses such as HIV-1 synthesize their provi-
ral DNA in macrophages, which contain limited dNTP pools. Our pre-
vious steady and pre-steady-state kinetic analysis revealed that
lentiviral RTs are capable of synthesizing DNA in the low dNTP con-
centrations found in macrophages, while in the same condition
oncoretroviral RTs fail. This unique capability of HIV-1 has been at-
tributed to RTs tight binding to dNTPs (Diamond et al., 2004). Thus,
it is intriguing to elucidate the mechanistic and structural features
of the HIV-1 RT dNTP-binding pocket.
Molecular manipulation of both the HIV-1 RT residue 114 and the
incoming dNTP substrate support that there is a mechanistic volume
requirement between the side chain at residue 114 and the sugar
moiety of the incoming dNTP substrate. In addition the mutations
that were generated in this study had minimal impact on the proces-
sivity of RT with the exception of A114V (Fig. 1S). This suggests that
the A114V mutations may result in larger structural changes thataffect RT interaction with the template primers as well as dNTPs.
We have previously demonstrated that the Q151 residue, which di-
rectly contacts the 3′ OH of the incoming dNTP via a hydrogen
bond, plays an important role in the tight dNTP binding afﬁnity of
HIV-1 RT (Weiss et al., 2002). The Q151N mutation was found to
signiﬁcantly reduce not only the dNTP binding afﬁnity of RT but
also the transduction of HIV-1 vectors bearing the Q151N mutation
in cells containing low dNTP concentrations (Jamburuthugoda et al.,
2006). As shown in Fig. 5 we further demonstrated that mutations at
residue 114 impact vector transduction speciﬁcally in cells containing
low dNTP concentrations.
Interestingly, as shown in Table 2, the A114C mutation prompted
a larger increase in the Kd values of purine nucleotide substrates
when compared to pyrimidine nucleotides. One simple explanation
for this differential effect on these two groups of nucleotide sub-
strates could be that the larger base moieties of purines require an in-
creased space in the active site of RT, compared to the pyrimidine
nucleotides. The mutation A114C might reduce this space, causing a
decrease in the binding of purine substrates to RT and an increase
in their Kd. A second explanation can be generated through past stud-
ies done with other DNA polymerases. It's been previously shown
that the nucleotide selectivity can be affected by residues at or around
the steric gate in the polymerase active site, which allows polymer-
ases to discriminate between natural/correct dNTPs and nonnatural/
incorrect dNTPs (DeLucia et al., 2006). Therefore, it is possible that
the A114C mutation structurally inﬂuences the steric gate residue of
HIV-1 RT, Tyr115 (Klarmann et al., 2007).
Our biochemical and virological results support that like the
Q151N HIV-1 RT mutant, the A114 RT mutants enzymatically mimic
oncoretroviral RTs such as MuLV RT and Avian Sarcoma Virus (ASV)
RT which both efﬁciently synthesize DNA only at the high dNTP con-
centrations found in dividing cells (Lewis and Emerman, 1994). How-
ever, while the Q151N HIV-1 RT mutation reduces the dNTP binding
afﬁnity through a lost interaction with the sugar moiety of a dNTP
substrate, the bulky mutations at 114 appears to reduce the dNTP
binding afﬁnity by occupying the space in the pocket where the
sugar moiety of dNTP normally binds RT. This is mechanistically sup-
ported by the observation with acyTTP incorporation.
This study demonstrates a unique way to modulate the entry of a
dNTP substrate within the dNTP-binding pocket of HIV-1 RT. Further-
more, our HIV-1 vector experiment conﬁrmed that the reduction of
the RT dNTP binding afﬁnity is one way to make HIV-1 mimic oncor-
etroviruses in terms of their distinct cell type tropism.
Materials and methods
Chemicals and cell lines
Oligonucleotides and primers were purchased from Integrated
DNA Technology. Escherichia coli, XL1Blues (Invitrogen), were used
for the construction of plasmids and BL21 (Novagen, WI) for the over-
expression of HIV-1 RT. MRC5 human lung ﬁbroblasts (HLFs) were a
kind gift from Dr. Toru Tokimoto (University of Rochester). The
293FTs used for production of viral vectors were purchased from Invi-
trogen. dTTP was purchased from USB Affymatrix and acyclic dTTP
from New England Biolabs. Primers were labeled with [γ-32P] ATP
(Amersham Biosciences).
Molecular modeling
Mutations were made with PyMOL (Schrodinger, 2010) manually
selecting the optimal rotamer for serine or cysteine at residue 114 of
HIV-1 reverse transcriptase from Huang et al. (1998). These were
then energy minimized with AMBER 9.0 with 500 cycles (250 stee-
pest descent) with implicit solvent. Mutations were visualized with
VMD with the residues 113, 115, 151, and 184 (Humphrey et al.,
400 S.K. Van Cor-Hosmer et al. / Virology 422 (2012) 393–4011996). The distances from the Cβ or hydroxyl group of the amino acid
at 114 of RT from the 3′ OH of the dTTP were calculated with the min-
imized PDB models using Sirius 1.2.
Construction and puriﬁcation of HIV-1 RT residue 114 mutant proteins
Mutations in residue 114 of the HIV-1 RT gene were introduced
through the ampliﬁcation of pET28 containing HXB2 HIV-1 RT by
PCR-based site directed mutagenesis (Stragene). RT homodimers de-
rived from HIV-1 (NL4-3) were hexahistidine-tagged (Kim, 1997;
Weiss et al., 2004) and expressed using an overexpression system in
BL21 E. coli. RT was puriﬁed using Ni2+ chelation chromatography
as described previously (Diamond et al., 2004; Weiss et al., 2004).
1 L cultures produced 1.5 μg of puriﬁed p66/p66 homodimers. The
puriﬁed RT was analyzed by 10% SDS-polyacrylamide gel using
1.5 μg of bovine serum albumin (Sigma), as a control.
Primer extension reaction of HIV-1 RT
The primer extension assay was conducted as previously de-
scribed (Diamond et al., 2004). Brieﬂy, a 38-mer RNA template (5′
AAGCUUGGCUGCAGAAUAUUGCUAGCGGGAAUUCGGCGCG-3′) was
annealed to a 17-mer extend T primer (5′ CCGAATTCCCGCTAGCAA-
TATTC 3′), 32P-labeled at the 5′ end, with a T4 polynucleotide kinase.
Reactions with a ﬁnal volume of 20 μl contained 20 nM of the tem-
plate/primer (T/P) and all 4 dNTPs in varying concentrations (250,
100, 25, 5, 1, 0.5, 0.25, and 0.1 μM). Reactions were incubated at
37 °C for 5 min then quenched with 40 mM EDTA. These reaction con-
ditions allow multiple rounds of primer extension. The amount of RT
used in the titration reaction was determined by the dilution of RT
that produced 50% T/P extension at 250 μM dNTP concentration. We
also preformed a single round primer extension reaction. In this reac-
tion only one of the following nucleotides were added, dTTP, or
acyTTP, in concentrations described in the ﬁgure legends.
Steady-state kinetic analysis of HIV-1 RT proteins
The reaction conditions of the steady-state kinetic analysis were
identical to the primer extension reactions. The reactions were re-
peated with eight dNTP concentrations of dTTP (1000, 400, 200, 80,
16, 6.4, 3.2, 0.28 μM) and acyTTP (300, 200, 150, 75, 40, 20, 5,
1 μM). Single nucleotide incorporation was measured on a polyacryl-
amide-urea gel and quantitated by phosphorimaging analysis using
OptiQuant software (PerkinElmer Life Sciences). The kcat and Km
values were determined using the Michaelis–Menten equation.
Pre-steady-state kinetic analysis of HIV-1 RT proteins
To determine the concentration of active WT and A114C RT,
single-turnover burst assays were performed as described before
(Jamburuthugoda et al., 2008). Brieﬂy 100 nM of a 5′ end 32P-labeled
23-mer extend-T primer and 200 nM of cold primer were annealed to
a 38-mer RNA template and extended with 100 nM WT or A114C RT
in presence of 800 μM dTTP for single round incorporation and rapid-
ly quenched with EDTA at different time points using the Kintek RFQ3
machine. The samples were then analyzed on a 14% sequencing gel
under denaturing conditions and the percent of extended product
was quantiﬁed (Quantity One 1-D analysis software, Biorad). The
product formation at each time point was plotted and ﬁtted to
Eq. (1), which determined the concentration of active RT (amplitude
of the burst). The pre-steady-state reactions with 200 nM active pro-
teins and 50 nM T/P complexes were performed to assess the ob-
served rates of product formation (kobs) at ﬁve or six time points in
duplicate per dNTPs concentration. This was performed for each
dNTPs (dTTP, dATP, dCTP, dGTP) and acyTTP, a dNTP analog. The
kobs values were then ﬁtted to Eq. (2) to yield kd and kpol. The datawas curve-ﬁtted with nonlinear regression to Eqs. (1) and (2) with
KaleidaGraph as described previously (Weiss et al., 2004).
Product½  ¼ Amp 1−exp −kobstð Þ½  þ ksstð Þ ð1Þ
kobs¼kpol dNTP½ = Kd þ dNTP½ ð Þ ð2Þ
HIV-1 vector construction and cell transduction
The D3HIV-GFP virus expresses eGFP and all HIV-1 NL4-3 proteins
except Nef and Env. It was pseudotyped with VSV-G as previously de-
scribed (Jamburuthugoda et al., 2008). The construction of the A114S,
A114C, and A114V mutants was carried out using a site directed mu-
tagenesis kit (Stragene). 293FTs (Invitrogen) were transfected with
A114S, A114C, A114V or WT pD3HIV-GFP and pVSV-G. Cells were
washed after 24 h. Supernatant was collected at 48 and 72 h after
transfection. The collected supernatant was spun in an ultra centri-
fuge (Beckman) with a SW-28 rotor at 22 k for 2 h. The viral pellets
were collected from each spin and treated with DNase and stored at
−80 °C. The vectors were normalized by p24 levels, which were de-
termined by an enzyme-linked immunosorbent assay system
(PerkinElmer).
HLFs were grown in either media containing 0.2% FBS (serum
starved) or 10% FBS for 48 h before transduction. Two hours post
transduction HLFs were treated with 10 μg/ml of Polybrene (Sigma)
and 1 mM dNs. Vectors were normalized to equal p24 amounts
(5×105 pg/mL). 24 h after transduction HLFs were washed with
DPBS and re-treated with 1 mM of dNs. Cells were washed again at
48 h and harvested. The cells were monitored for GFP expression by
ﬂuorescent activated cell sorting using the FL-1 channel of a C6
Flow Cytometer (Accuri). Percent transduction was determined
using FlowJo software (version 8.8.5, Tree Star, Inc). Statistical analy-
sis and graphing was preformed with Prism 4 (GraphPad Software
Inc). The transduction experiments were repeated in triplicate with
the same batch of viral vector.
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